Up-regulation of cyclooxygenase-2-derived prostaglandin E2 in colon cancer cells resistant to 5-fluorouracil

Journal of the Korean Surgical Society

Volumn 81, Issue 2, 2011, Pages 115-121

  Choi, Cheol Hee ^a   Lee, Tae Bum ^a   Lee, Yeon Ah ^a   Choi, Suk ^a   Kim, Kyung Jong ^a  

^a Chosun University College of Medicine   (South Korea)

Author keywords

5 Fluorouracil; Acquired resistance; Colon neoplasms; Cyclooxygenase 2; Prostaglandin E2

Indexed keywords

EID: 80051913636     PISSN: 12260053     EISSN: 20930488     Source Type: Journal    
DOI: 10.4174/jkss.2011.81.2.115     Document Type: Article

References (31)

1. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-8. (Pubitemid 37328853)
2. Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: A systematic review and meta-analysis. J Clin Oncol 2004;22: 529-36. (Pubitemid 41079782)
3. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000;6: 1322-7. (Pubitemid 30226214)
4. Boyer J, McLean EG, Aroori S, Wilson P, McCulla A, Carey PD, et al. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin Cancer Res 2004;10:2158-67. (Pubitemid 38375578)
5. Wang W, McLeod HL, Cassidy J. Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int J Cancer 2003;104:504-11. (Pubitemid 36323923)
6. Meyers M, Wagner MW, Hwang HS, Kinsella TJ, Boothman DA. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res 2001;61:5193-201. (Pubitemid 32681553)
7. Mirjolet JF, Didelot C, Barberi-Heyob M, Merlin JL. G(1)/S but not G(0)/G(1)cell fraction is related to 5-fluorouracil cytotoxicity. Cytometry 2002;48:6-13. (Pubitemid 34454140)
8. Brown JR, DuBois RN. COX-2: A molecular target for colorectal cancer prevention. J Clin Oncol 2005;23:2840-55. (Pubitemid 46179475)
9. Yamauchi T, Watanabe M, Kubota T, Hasegawa H, Ishii Y, Endo T, et al. Cyclooxygenase-2 expression as a new marker for patients with colorectal cancer. Dis Colon Rectum 2002;45:98-103. (Pubitemid 34072758)
10. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999;18:7908-16. (Pubitemid 30066236)
11. Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 2000;37:431-502. (Pubitemid 32173442)
12. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: A molecular target for cancer prevention and treatment. Trends Pharmacol Sci 2003;24:96-102. (Pubitemid 36135884)
13. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA. The cyclooxygenase- 2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 2000;60:5040-4.
14. Mizutani Y, Kamoi K, Ukimura O, Kawauchi A, Miki T. Synergistic cytotoxicity and apoptosis of JTE-522, a selective cyclooxygenase-2 inhibitor, and 5-fluorouracil against bladder cancer. J Urol 2002;168:2650-4. (Pubitemid 35402710)
15. Wilgus TA, Breza TS Jr, Tober KL, Oberyszyn TM. Treatment with 5-fluorouracil and celecoxib displays synergistic regression of ultraviolet light B-induced skin tumors. J Invest Dermatol 2004;122:1488-94. (Pubitemid 38757232)
16. Jung GR, Kim KJ, Choi CH, Lee TB, Han SI, Han HK, et al. Effect of betulinic acid on anticancer drug-resistant colon cancer cells. Basic Clin Pharmacol Toxicol 2007;101:277-85. (Pubitemid 350194804)
17. Pieters R, Huismans DR, Leyva A, Veerman AJ. Adaptation of the rapid automated tetrazolium dye based (MTT) assay for chemosensitivity testing in childhood leukemia. Cancer Lett 1988;41:323-32.
18. Cetta F, Goetz FW. Ovarian and plasma prostaglandin E and F levels in brook trout (Salvelinus fontinalis) during pituitary-induced ovulation. Biol Reprod 1982;27:1216-21.
19. Arango D, Corner GA, Wadler S, Catalano PJ, Augenlicht LH. c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo. Cancer Res 2001;61:4910-5. (Pubitemid 32691909)
20. Kim HJ, Lee SC, Lee IK, Kang WK, Oh ST, Chang SK. The synergistic cell killing effects by the transduction of the w-p53 Gene and 5-FU administration in colon cancer cell lines. J Korean Surg Soc 2007;73:481-9.
21. Rand A, Glenn KS, Alvares CP, White MB, Thibodeau SM, Karnes WE Jr. p53 functional loss in a colon cancer cell line with two missense mutations (218leu and 248trp) on separate alleles. Cancer Lett 1996;98:183-91.
22. Subbaramaiah K, Hart JC, Norton L, Dannenberg AJ. Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways. J Biol Chem 2000;275:14838-45. (Pubitemid 30337196)
23. Mathieu A, Remmelink M, D'Haene N, Penant S, Gaussin JF, Van Ginckel R, et al. Development of a chemoresistant orthotopic human nonsmall cell lung carcinoma model in nude mice: Analyses of tumor heterogenity in relation to the immunohistochemical levels of expression of cyclooxygenase- 2, ornithine decarboxylase, lung-related resistance protein, prostaglandin E synthetase, and glutathione- S-transferase-alpha (GST)-alpha, GST-mu, and GST-pi. Cancer 2004;101:1908-18. (Pubitemid 39328201)
24. Mercer SJ, Di Nicolantonio F, Knight LA, Gabriel FG, Whitehouse PA, Sharma S, et al. Rapid up-regulation of cyclooxygenase- 2 by 5-fluorouracil in human solid tumors. Anticancer Drugs 2005;16:495-500. (Pubitemid 40685733)
25. Debucquoy A, Goethals L, Geboes K, Roels S, Mc Bride WH, Haustermans K. Molecular responses of rectal cancer to preoperative chemoradiation. Radiother Oncol 2006;80: 172-7. (Pubitemid 44301536)
26. Irie T, Tsujii M, Tsuji S, Yoshio T, Ishii S, Shinzaki S, et al. Synergistic antitumor effects of celecoxib with 5-fluorouracil depend on IFN-gamma. Int J Cancer 2007;121:878-83. (Pubitemid 47106220)
27. Réti A, Pap E, Zalatnai A, Jeney A, Kralovánszky J, Budai B. Co-inhibition of cyclooxygenase-2 and dihydropyrimidine dehydrogenase by non-steroidal anti-inflammatory drugs in tumor cells and xenografts. Anticancer Res 2009;29:3095-101.
28. Tachimori A, Yamada N, Amano R, Ohira M, Hirakawa K. Combination therapy of S-1 with selective cyclooxygenase- 2 inhibitor for liver metastasis of colorectal carcinoma. Anticancer Res 2008;28(2A):629-38. (Pubitemid 351578902)
29. Wang D, DuBois RN. Cyclooxygenase 2-derived prostaglandin E2 regulates the angiogenic switch. Proc Natl Acad Sci U S A 2004;101:415-6. (Pubitemid 38084650)
30. Chang SH, Liu CH, Conway R, Han DK, Nithipatikom K, Trifan OC, et al. Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci U S A 2004;101:591-6. (Pubitemid 38084681)
31. Ueno T, Chow LW, Toi M. Increases in circulating VEGF levels during COX-2 inhibitor treatment in breast cancer patients. Biomed Pharmacother 2006;60:277-9.